Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 8/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.36 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28944893 | 0.89 | CA2 (0.48) | NOD1PPARDKMT2APOLBLPAR3 | |
| SCHEMBL28944892 | 0.89 | CA2 (0.48) | NOD1PPARDKMT2APOLBLPAR3 | |
| SCHEMBL15623817 | 0.79 | NOD1 (0.61) | NOD1KMT2ASLC6A5 | |
| SCHEMBL22690652 | 0.77 | KMT2A (0.36) | NOD1PPARDKMT2APOLBLPAR3 | |
| SCHEMBL22690653 | 0.77 | KMT2A (0.36) | NOD1PPARDKMT2APOLBLPAR3 | |
| SCHEMBL4627107 | 0.76 | NOD1 (0.62) | NOD1KMT2ASLC6A5 | |
| SCHEMBL15680298 | 0.74 | NOD1 (0.56) | NOD1PPARDKMT2ASLC6A5 | |
| SCHEMBL9828089 | 0.74 | NOD1 (0.70) | NOD1KMT2ASLC6A5 | |
| SCHEMBL2383184 | 0.73 | PPARD (0.54) | PPARDKMT2A | |
| SCHEMBL22503896 | 0.73 | NOD1 (0.55) | NOD1KMT2ASLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023225336-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225320-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225359-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| WO-2022115451-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2022-06-02 | — | — | WO | disclosed |